Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia.

Tonstad S, Pometta D, Erkelens DW, Ose L, Moccetti T, Schouten JA, Golay A, Reitsma J, Del Bufalo A, Pasotti E, et al.

Eur J Clin Pharmacol. 1994;46(5):405-10.

PMID:
7957533
2.

One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.

Finer N, James WP, Kopelman PG, Lean ME, Williams G.

Int J Obes Relat Metab Disord. 2000 Mar;24(3):306-13.

PMID:
10757623
3.

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.

Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J.

Diabetes Care. 1998 Aug;21(8):1288-94.

PMID:
9702435
4.

Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.

Micić D, Ivković-Lazar T, Dragojević R, Jorga J, Stokić E, Hajduković Z.

Med Pregl. 1999 Sep-Oct;52(9-10):323-33. English, Croatian.

PMID:
10624380
5.
6.

A one-year trial to assess the value of orlistat in the management of obesity.

James WP, Avenell A, Broom J, Whitehead J.

Int J Obes Relat Metab Disord. 1997 Jun;21 Suppl 3:S24-30.

PMID:
9225173
7.

[Pharmacological therapy of obesity].

Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian.

PMID:
18773755
8.

The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.

Muls E, Kolanowski J, Scheen A, Van Gaal L; ObelHyx Study Group.

Int J Obes Relat Metab Disord. 2001 Nov;25(11):1713-21.

PMID:
11753595
9.

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.

Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M.

Lancet. 1998 Jul 18;352(9123):167-72.

PMID:
9683204
10.

Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.

Halpern A, Mancini MC, Suplicy H, Zanella MT, Repetto G, Gross J, Jadzinsky M, Barranco J, Aschner P, Ramirez L, Matos AG.

Diabetes Obes Metab. 2003 May;5(3):180-8.

PMID:
12681025
11.

Orlistat fails to alter postprandial plasma lipid excursions or plasma lipases in normal-weight male volunteers.

Shepard TY, Jensen DR, Blotner S, Zhi J, Guerciolini R, Pace D, Eckel RH.

Int J Obes Relat Metab Disord. 2000 Feb;24(2):187-94.

PMID:
10702769
12.

Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group.

Van Gaal LF, Broom JI, Enzi G, Toplak H.

Eur J Clin Pharmacol. 1998 Apr;54(2):125-32.

PMID:
9626916
13.

Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study.

Drent ML, Larsson I, William-Olsson T, Quaade F, Czubayko F, von Bergmann K, Strobel W, Sjöström L, van der Veen EA.

Int J Obes Relat Metab Disord. 1995 Apr;19(4):221-6.

PMID:
7627244
14.
15.

On the effects of dietary n-3 fatty acids (Maxepa) on plasma lipids and lipoproteins in patients with hyperlipidaemia.

Simons LA, Hickie JB, Balasubramaniam S.

Atherosclerosis. 1985 Jan;54(1):75-88.

PMID:
3888229
16.

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.

Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J, Heymsfield SB.

JAMA. 1999 Jan 20;281(3):235-42. Erratum in: JAMA 1999 Apr 7;281(13):1174.

PMID:
9918478
17.

[Effect of orlistat therapy on carbohydrate, lipid, vitamin and hormone plasma levels in obese subjects].

Czerwieńska B, Kokot F, Franek E, Irzyniec T, Wiecek A.

Pol Arch Med Wewn. 2004 Dec;112(6):1415-23. Polish.

PMID:
15962606
19.

The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia.

Nakou ES, Filippatos TD, Kiortsis DN, Derdemezis CS, Tselepis AD, Mikhailidis DP, Elisaf MS.

Expert Opin Pharmacother. 2008 Dec;9(18):3151-8. doi: 10.1517/14656560802548430 .

PMID:
19040336
20.

Orlistat in the long-term treatment of obesity in primary care settings.

Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR.

Arch Fam Med. 2000 Feb;9(2):160-7.

PMID:
10693734

Supplemental Content

Support Center